In particular, for patients undergoing treatment with EGFR TKIs [48], there is evidence of poor PFS and cancer-specific survival [50], as well as a correlation with lymph node metastases [50]. Here, EGFR is linked to metastatic malignant neoplasm in the lymph nodes.